ChAdOx1 RVF

BIOLOGICAL4 trials

Sponsors

University of Oxford

Conditions

RVFRift Valley FeverRift Valley fever

Early Phase 1

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

CompletedNCT04754776

University of OxfordRift Valley Fever

Start: 2021-06-11End: 2022-04-06Updated: 2023-05-19

Phase 1

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

CompletedNCT04672824

University of OxfordRift Valley Fever, RVF

Start: 2022-05-31End: 2022-12-15Updated: 2023-02-06

Phase 2

A study to assess whether a new vaccine called ChAdOx1 RVF will be safe and work well in generating an immune response against Rift Valley Fever in adults in Kenya

Active, not recruitingPACTR202406789723926

University of OxfordRift Valley fever

Start: 2025-06-02Target: 240Updated: 2026-09-14

Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)

Active, not recruitingNCT06799234

University of OxfordRift Valley Fever

Start: 2025-07-08End: 2027-03-31Updated: 2025-11-17

Related Papers

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.

2025-11-11

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.

2023-04-1320 citations